NCT03122730View on ClinicalTrials.gov

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

March 1, 2019

Study Completion Date

May 30, 2019

Conditions
Pulmonary Hypertension
Interventions
COMBINATION_PRODUCT

VentaProst

epoprostenol for inhalation via custom drug delivery system

Trial Locations (3)

60612

Rush University Medical Center, Chicago

94305

Stanford University Medical Center, Stanford

02111

Tufts Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Aerogen Pharma Limited

INDUSTRY

NCT03122730 - VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB | Biotech Hunter | Biotech Hunter